Caraco has addressed US 'Form 483' quality concerns, Sun confirms
This article was originally published in Scrip
Sun Pharmaceutical Industries has said that its US arm, Caraco, has no pending unaddressed Form 483s, which pertain to the US FDA's observations on deficiencies in quality control systems, at its manufacturing sites, bringing relief to investors jittery over a spate of recent regulatory actions against a clutch of Indian firms.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.